Antithrombotic effects of saratin on human atherosclerotic plaques

Research article published in Thromb Haemost (2004)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Research reportФармакология секрета слюнных желёзРазработка лекарственных препаратовVilahur G et al. · Thromb Haemost, 2004

Abstract

Platelets play a primary role in thrombus formation after plaque rupture. Platelets recognize the exposed collagen via Von Willebrand factor (VWF) and become activated. Saratin, an inhibitor of the VWF-dependent binding of platelets to collagen, may reduce the thrombotic risk associated to atherosclerosis. Our objective was to evaluate the antithrombotic effects of local treatment with saratin on human atherosclerotic lesions. Thrombus formation was assessed by the deposition of (111)In-platelets on different human atherosclerotic lesions under three local shear conditions (800,1700 and 3400/s) with blood derived from catheterized pigs. Human atherosclerotic lesions were locally treated with saratin (30 microg/ml) at 37 degrees C for 5 min and placed in the chamber. Under stenotic shear conditions of 800/s, saratin significantly (p<0.05) reduced platelet deposition triggered by human denuded vessel wall (44%), fatty streaks (47%), severely damaged vessel (50%) and atherosclerotic plaque (57%). Thrombus characterization by immunohistochemistry showed also a reduction in fibrin deposition in treat-ed vessels. These results suggest that the local site-specific treatment with saratin inhibits atherosclerotic plaque thrombogenicity at haemodynamic conditions typical of moderately stenotic coronary arteries.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't

Indexed MeSH termsAnimalsArteriosclerosisBlood PlateletsCollagenFibrinolytic AgentsHumansIn Vitro TechniquesIndium RadioisotopesPlatelet AdhesivenessSalivary Proteins and PeptidesSus scrofaThrombosis

Резюме

Platelets play a primary role in thrombus formation after plaque rupture. Platelets recognize the exposed collagen via Von Willebrand factor (VWF) and become activated.

Почему это важно для гирудотерапии

This ex-vivo study evaluated saratin, described as an inhibitor of von Willebrand factor-dependent platelet binding to collagen, as a local treatment to reduce thrombus formation on human atherosclerotic lesions. Using blood from catheterized pigs perfused over treated plaques, saratin (30 microg/ml) significantly reduced platelet deposition on denuded vessel wall, fatty streaks, severely damaged vessel, and atherosclerotic plaque at 800/s shear, and also reduced fibrin deposition. The abstract does not identify saratin's biological origin and makes no mention of leeches, the leech secretome, or hirudotherapy. There is no defensible connection to ASH's domain based on this abstract. The study used pig blood perfused over human tissue with no clinical data.

Цитирование

Antithrombotic effects of saratin on human atherosclerotic plaques.

Vilahur G et al. · Thromb Haemost, 2004

DOI

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Salivary Gland Secretion Anti-Inflammatory Mechanisms Salivary Complex Drug Pipeline Drug Development Direct Thrombin Inhibitors Atherosclerosis Mechanisms Cardiovascular Otolaryngology Post-Thrombotic Syndrome Hemostasis

Отказ от ответственности — научно-образовательная информация

Информация на данной странице предоставлена исключительно в образовательных и информационных целях и не является медицинской консультацией, диагнозом или рекомендациями по лечению. Резюме клинических данных отражают опубликованную рецензируемую литературу и не подразумевают терапевтическую эффективность за пределами показаний, одобренных FDA.

Разрешение FDA 510(k) для медицинских пиявок ограничено конкретными показаниями. Исследовательские и офф-лейбл применения обозначены соответствующим образом. Перед клиническим использованием практикующим врачам следует руководствоваться действующими рекомендациями FDA, локальными протоколами и применимыми нормативно-правовыми актами штата.

ASH поддерживает строгую доказательную оценку всех применений гирудотерапии посредством контролируемых клинических исследований и рецензируемых публикаций.

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026